STOCK TITAN

[Form 4] Solid Biosciences Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Solid Biosciences Inc. reported that its Chief Operating Officer, David T. Howton, was granted equity awards on 08/14/2025 consisting of an employee stock option to buy 150,000 shares at an exercise price of $6.17 per share with an expiration date of 08/14/2035, and 75,000 restricted stock units (RSUs) that each convert into one share. After these grants, Mr. Howton beneficially owns 150,000 option shares and 75,000 RSUs, all held directly. The RSUs and the option vest over four years: 50% vests on the second anniversary of the grant and 25% vests on each of the third and fourth anniversaries.

Solid Biosciences Inc. ha comunicato che il suo Chief Operating Officer, David T. Howton, ha ricevuto premi azionari in data 14/08/2025 comprensivi di un'opzione su azioni dei dipendenti per l'acquisto di 150.000 azioni a un prezzo di esercizio di $6,17 per azione con scadenza il 14/08/2035, e di 75.000 restricted stock units (RSU) ognuna convertibile in una azione. Dopo tali assegnazioni, il Sig. Howton detiene in via beneficiaria 150.000 azioni opzionate e 75.000 RSU, tutte detenute direttamente. Le RSU e l'opzione maturano su un periodo di quattro anni: il 50% matura al secondo anniversario della data di assegnazione e il 25% matura al terzo e al quarto anniversario.

Solid Biosciences Inc. informó que su Chief Operating Officer, David T. Howton, recibió concesiones de capital el 14/08/2025 consistentes en una opción sobre acciones de empleado para comprar 150.000 acciones a un precio de ejercicio de $6,17 por acción con fecha de vencimiento el 14/08/2035, y 75.000 unidades restringidas de acciones (RSU) que se convierten en una acción cada una. Tras estas concesiones, el Sr. Howton posee en beneficio 150.000 acciones opcionadas y 75.000 RSU, todas mantenidas directamente. Las RSU y la opción consolidan derechos a lo largo de cuatro años: el 50% se consolida en el segundo aniversario de la concesión y el 25% en cada uno del tercero y cuarto aniversarios.

Solid Biosciences Inc.는 최고운영책임자(COO) David T. Howton이 2025년 8월 14일에 지분 보상을 받았다고 보고했습니다. 보상 내용은 행사 가격이 주당 $6.17이고 만료일이 2035년 8월 14일150,000주 매수용 종업원 스톡옵션과 각각 1주로 전환되는 75,000개의 제한부주식단위(RSU)입니다. 이 부여 후 Howton 씨는 직접 보유 방식으로 혜택상 150,000주의 옵션 주식과 75,000개의 RSU를 소유하게 되었습니다. RSU와 옵션은 4년 동안 베스팅되며, 부여일로부터 2주년에는 50%가 베스트되고 3주년과 4주년에는 각각 25%가 베스트됩니다.

Solid Biosciences Inc. a annoncé que son Chief Operating Officer, David T. Howton, s'est vu attribuer des rémunérations en actions le 14/08/2025, comprenant une option d'achat d'actions salariés portant sur 150 000 actions au prix d'exercice de $6,17 par action, expirant le 14/08/2035, et 75 000 unités d'actions restreintes (RSU) convertibles chacune en une action. Après ces attributions, M. Howton détient au bénéfice 150 000 actions optionnées et 75 000 RSU, toutes détenues directement. Les RSU et l'option acquièrent des droits sur quatre ans : 50 % acquiert droit au 2e anniversaire de l'attribution et 25 % à chacun des 3e et 4e anniversaires.

Solid Biosciences Inc. berichtete, dass sein Chief Operating Officer, David T. Howton, am 14.08.2025 Aktienzuwendungen erhalten hat, und zwar eine Mitarbeiteraktienoption zum Kauf von 150.000 Aktien zu einem Ausübungspreis von $6,17 je Aktie mit Ablaufdatum 14.08.2035 sowie 75.000 Restricted Stock Units (RSUs), die jeweils in eine Aktie umgewandelt werden. Nach diesen Zuwendungen besitzt Herr Howton wirtschaftlich 150.000 Optionsaktien und 75.000 RSUs, alle direkt gehalten. Die RSUs und die Option vesten über vier Jahre: 50 % vesten am zweiten Jahrestag der Gewährung und jeweils 25 % am dritten und vierten Jahrestag.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: The filing documents standard executive equity compensation: long-dated options plus RSUs with back-loaded vesting, aligning retention incentives.

The award package pairs a ten-year option with RSUs and a vesting schedule weighted toward the second year, which may be intended to retain the COO through multi-year operational milestones. The $6.17 exercise price sets the strike level for the option; the grant size (225,000 total equity-linked units) is meaningful for a senior officer but must be assessed relative to company headcount and outstanding shares to judge dilution. All holdings are reported as direct ownership, simplifying governance considerations.

TL;DR: Form 4 properly discloses grant details and direct ownership; vesting terms and option life are clearly stated.

The disclosure includes requisite details: transaction date, exercise price, quantity, expiration, and vesting schedule for RSUs and options. Signature indicates filing by attorney-in-fact, which is acceptable when authorized. No derivative dispositions, sales, or complex indirect holdings are reported, reducing immediate compliance risk. This is a routine insider compensation disclosure rather than a market-moving transaction.

Solid Biosciences Inc. ha comunicato che il suo Chief Operating Officer, David T. Howton, ha ricevuto premi azionari in data 14/08/2025 comprensivi di un'opzione su azioni dei dipendenti per l'acquisto di 150.000 azioni a un prezzo di esercizio di $6,17 per azione con scadenza il 14/08/2035, e di 75.000 restricted stock units (RSU) ognuna convertibile in una azione. Dopo tali assegnazioni, il Sig. Howton detiene in via beneficiaria 150.000 azioni opzionate e 75.000 RSU, tutte detenute direttamente. Le RSU e l'opzione maturano su un periodo di quattro anni: il 50% matura al secondo anniversario della data di assegnazione e il 25% matura al terzo e al quarto anniversario.

Solid Biosciences Inc. informó que su Chief Operating Officer, David T. Howton, recibió concesiones de capital el 14/08/2025 consistentes en una opción sobre acciones de empleado para comprar 150.000 acciones a un precio de ejercicio de $6,17 por acción con fecha de vencimiento el 14/08/2035, y 75.000 unidades restringidas de acciones (RSU) que se convierten en una acción cada una. Tras estas concesiones, el Sr. Howton posee en beneficio 150.000 acciones opcionadas y 75.000 RSU, todas mantenidas directamente. Las RSU y la opción consolidan derechos a lo largo de cuatro años: el 50% se consolida en el segundo aniversario de la concesión y el 25% en cada uno del tercero y cuarto aniversarios.

Solid Biosciences Inc.는 최고운영책임자(COO) David T. Howton이 2025년 8월 14일에 지분 보상을 받았다고 보고했습니다. 보상 내용은 행사 가격이 주당 $6.17이고 만료일이 2035년 8월 14일150,000주 매수용 종업원 스톡옵션과 각각 1주로 전환되는 75,000개의 제한부주식단위(RSU)입니다. 이 부여 후 Howton 씨는 직접 보유 방식으로 혜택상 150,000주의 옵션 주식과 75,000개의 RSU를 소유하게 되었습니다. RSU와 옵션은 4년 동안 베스팅되며, 부여일로부터 2주년에는 50%가 베스트되고 3주년과 4주년에는 각각 25%가 베스트됩니다.

Solid Biosciences Inc. a annoncé que son Chief Operating Officer, David T. Howton, s'est vu attribuer des rémunérations en actions le 14/08/2025, comprenant une option d'achat d'actions salariés portant sur 150 000 actions au prix d'exercice de $6,17 par action, expirant le 14/08/2035, et 75 000 unités d'actions restreintes (RSU) convertibles chacune en une action. Après ces attributions, M. Howton détient au bénéfice 150 000 actions optionnées et 75 000 RSU, toutes détenues directement. Les RSU et l'option acquièrent des droits sur quatre ans : 50 % acquiert droit au 2e anniversaire de l'attribution et 25 % à chacun des 3e et 4e anniversaires.

Solid Biosciences Inc. berichtete, dass sein Chief Operating Officer, David T. Howton, am 14.08.2025 Aktienzuwendungen erhalten hat, und zwar eine Mitarbeiteraktienoption zum Kauf von 150.000 Aktien zu einem Ausübungspreis von $6,17 je Aktie mit Ablaufdatum 14.08.2035 sowie 75.000 Restricted Stock Units (RSUs), die jeweils in eine Aktie umgewandelt werden. Nach diesen Zuwendungen besitzt Herr Howton wirtschaftlich 150.000 Optionsaktien und 75.000 RSUs, alle direkt gehalten. Die RSUs und die Option vesten über vier Jahre: 50 % vesten am zweiten Jahrestag der Gewährung und jeweils 25 % am dritten und vierten Jahrestag.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Howton David T

(Last) (First) (Middle)
C/O SOLID BIOSCIENCES INC.
500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)
CHARLESTOWN MA 02129

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) $6.17 08/14/2025 A 150,000 (1) 08/14/2035 Common Stock 150,000 $0.00 150,000 D
Restricted Stock Units (2) 08/14/2025 A 75,000 (1) (1) Common Stock 75,000 $0.00 75,000 D
Explanation of Responses:
1. The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary.
2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").
/s/ Kimberly Cornwell as attorney-in-fact for David Tyronne Howton 08/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did SLDB COO receive on 08/14/2025?

The COO was granted an employee stock option for 150,000 shares at an exercise price of $6.17 and 75,000 RSUs.

When do the RSUs and options vest for the SLDB grant?

The awards vest over four years: 50% of the original shares vest on the second anniversary of the grant, then 25% annually on the third and fourth anniversaries.

How long is the option exercisable for SLDB COO's grant?

The option has an expiration date of 08/14/2035, giving a ten-year potential term from the grant date.

Does the Form 4 show indirect ownership or complex transactions?

No; the Form 4 reports these awards as direct ownership and contains no dispositions or indirect holdings.

Who signed the Form 4 for David T. Howton?

The Form 4 was signed by Kimberly Cornwell as attorney-in-fact for David T. Howton on 08/18/2025.
Solid Bioscience

NASDAQ:SLDB

SLDB Rankings

SLDB Latest News

SLDB Latest SEC Filings

SLDB Stock Data

440.74M
65.52M
0.52%
103.98%
13.05%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CHARLESTOWN